News
Pfizer, Blackstone Partner to Advance Obesity Drug Development
Blackstone will fund up to $1.5 billion in development costs through 2028 to support Pfizer’s clinical programme for berobenatide, an investigational monthly GLP-1 receptor agonist being studied for chronic weight management and obesity-related conditions.
imphoenix82
- November 12, 2026
- 0 Comments
- 80 Views
-
